Jacques Näsström
Nessuna posizione attualmente
Storia della carriera di Jacques Näsström
Precedenti posizioni note di Jacques Näsström
Società | Posizione | Inizio | Fine |
---|---|---|---|
EGETIS THERAPEUTICS AB | Direttore/Membro del Consiglio | 21/04/2011 | 12/12/2012 |
Amministratore Delegato | 19/04/2011 | 16/06/2017 | |
Direttore Tecnico/Scientifico/R&S | 16/06/2017 | 01/12/2023 | |
Contatto Relazioni con gli Investitori | - | 16/06/2017 | |
Public Communications Contact | 24/06/2010 | - | |
Q-Med AB
Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | 01/01/2010 |
Karolinska Investment Fund KB
Karolinska Investment Fund KB Investment ManagersFinance Karolinska Investment Fund KB is a healthcare-focused fund based in Stockholm. Targeted portfolio companies are pharmaceutical, biotechnology and medical technology companies located in Sweden. | Direttore degli Investimenti | - | - |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Corporate Officer/Principal | 01/01/1986 | 01/01/2001 |
AngioGenetics AB
AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Corporate Officer/Principal | - | - |
Independent Pharmaceutica AB
Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Direttore/Membro del Consiglio | - | - |
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Direttore/Membro del Consiglio | - | - |
Accuro Immunology AB
Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Presidente | - | - |
Formazione di Jacques Näsström
University of Uppsala | Doctorate Degree |
Stockholm School of Economics | Masters Business Admin |
Statistiche
Distribuzione geografica
Svezia | 11 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
EGETIS THERAPEUTICS AB | Health Technology |
Aziende private | 7 |
---|---|
Accuro Immunology AB
Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Health Technology |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Health Technology |
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Commercial Services |
Independent Pharmaceutica AB
Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Distribution Services |
AngioGenetics AB
AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Health Technology |
Karolinska Investment Fund KB
Karolinska Investment Fund KB Investment ManagersFinance Karolinska Investment Fund KB is a healthcare-focused fund based in Stockholm. Targeted portfolio companies are pharmaceutical, biotechnology and medical technology companies located in Sweden. | Finance |
Q-Med AB
Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Jacques Näsström
- Esperienza